Filgrastim-txid (Nypozi)
Optional dilutionFull monograph review pending
U.S. label preparation
Nypozi · Optional dilution
- Preparation
- For IV dilution of the prefilled syringe, prepare 15 mcg/mL in 5% dextrose and add human albumin to a final 2 mg/mL. Saline can cause precipitation.
- Administration and handling
- Use the product-specific concentration and the compatible infusion materials listed in section 2.6.
Product and source details
Cipla USA Inc. · BLA761126
Product NDC: 69097-430, 69097-429
SPL effective 2025-05-01 | SPL version 1. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.